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Introduction
Polycystic ovary syndrome (PCOS) affects 6–10% of
women of reproductive age and is a common cause of
infertility [1]. Its clinical manifestations can include men-
strual irregularities, signs of androgen excess, and obe-
sity [1]. Trials focusing on pregnancy as an outcome may
place greater emphasis on anovulation as the identifying
symptom, rather than the presence of polycystic ovaries
or clinical hyperandrogenism [2]. Women with chronic
hyperandrogenism and irregular menstrual cycles
and/or polycystic ovaries appear to be at substantially
greater risk of insulin resistance than those with hyper-
androgenism and regular cycles [3,4]. It is, therefore,
essential that studies into the metabolic features of PCOS
should stratify affected women according to ovulatory
function (i.e. chronic oligomenorrhea/amenorrhea ver-
sus regular cycles). It has been shown that a propor-
tion of PCOS patients do not demonstrate any overt
abnormality in circulating androgens [1,5,6]. The opti-
mal management of PCOS is uncertain, and treatment
focuses on amelioration of the clinical features. The aim
of treatment is to restore ovulatory cycles so that preg-
nancy can be achieved. Clinical studies have shown
that metformin (500 mg three times per day or 850 mg
twice daily, with meals) administered to women with
PCOS increases the frequency of spontaneous ovula-
tion, menstrual regularity, and ovulatory response 
to clomiphene [7,8]. However, the long-term use of
insulin-sensitizing agents needed to prevent the poten-
tial complications of PCOS cannot be recommended
because of a lack of evidence regarding their safety and
efficacy [9]. Recent animal investigations have estab-
lished a role for calcium in oocyte activation and mat-
uration, resulting in the resumption and progression
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SUMMARY
Objective: The aim of this study was to evaluate the effects of calcium-vitamin D and metformin on the men-
strual cycle and ovulation in patients with polycystic ovary syndrome (PCOS).
Materials and Methods: In this pilot study, 60 infertile PCOS patients were enrolled in a randomized clinical
trial and divided into three equal groups. Group 1 received 1,000 mg of calcium and 400 IU of vitamin D per day,
orally. Group 2 received the same as Group 1, plus 1,500 mg/day of metformin. Group 3 received 1,500 mg/day
of metformin. The patients were treated for 3 months and followed up for a further 3 months. Regularity of
menses, number of large follicles (≥ 14 mm) and pregnancy rates were compared among the three groups.
Results: Generalized estimating equation tests showed that the number of dominant follicles (≥ 14 mm) during
the 2–3 months of follow-up was higher in the calcium-vitamin D plus metformin group than in either of the
other two groups (p = 0.03).
Conclusion: The effects of metformin and calcium-vitamin D in regulating the menstrual cycle suggest that they
could also be effective for the treatment of anovulation and oligomenorrhea, with possible consequences for
pregnancy rates in PCOS patients. [Taiwan J Obstet Gynecol 2009;48(2):142–147]
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of follicular development [10]. In 1974, Steinhardt et al
[11] proposed that calcium may have a universal role in
egg activation. Since then, the importance of calcium
in the regulation of both meiotic and mitotic cell divi-
sion cycles in mammalian oocytes has aroused consid-
erable interest [12]. Because of the importance of
calcium in both oocyte activation and maturation, it
was hypothesized that abnormalities in calcium homeo-
stasis may play a role in the pathogenesis of PCOS
[13]. Previous studies have suggested that vitamin D
also plays a role in reproductive functions. Vitamin D
receptors are expressed in the ovary and testis, sug-
gesting that vitamin D is active in these organs [14]. In
this pilot study, the effects of metformin and calcium-
vitamin D on folliculogenesis and menstrual regularity
were assessed in PCOS patients.
Materials and Methods
From February 2004, we enrolled 60 infertile women
aged 20–40 years old, who were referred to the Vali-e-Asr
Reproductive Health Research Center and who met the
Rotterdam criteria for PCOS [2]. Permission to per-
form this study was obtained from the ethical board of
the research committee of Tehran Medical University.
The subjects volunteered to participate after the pur-
pose of the study was explained to them. All patients
signed consent forms.
All patients underwent an extensive interview to ascer-
tain their demographic characteristics, completed a ques-
tionnaire regarding their dietary habits, and underwent
physical and clinical examinations, including sonogra-
phy and hormonal analyses. Diagnostic endocrine tests
included serum levels of prolactin, thyroid-stimulating
hormone, follicle-stimulating hormone and luteinizing
hormone, and urinary and serum levels of calcium. Base-
line transvaginal sonography was performed on the third
day of the menstrual cycle. In order to determine follic-
ular growth, transvaginal sonography was performed
every 3 days from day 8 of menstruation until the appear-
ance of at least one dominant follicle (14 mm).
According to the Rotterdam criteria, the presence
of two of the three following characteristics were re-
quired for inclusion in the study: (1) oligomenorrhea/
amenorrhea, (2) chemical or clinical findings of hyper-
androgenism, and (3) polycystic ovaries on transvagi-
nal sonography. Patients with systemic diseases such
as Cushing’s syndrome, hyperparathyroidism or hyper-
prolactinemia, androgen secreting tumors, history of
abdominal/pelvic surgery, coexisting male factor infertil-
ity, or abnormal hysterosalpingography were excluded
from the study.
Patients were divided into three groups, each contain-
ing 20 women, using a random number table. Patients
in Group 1 received 1,000 mg of calcium and 400 IU of
vitamin D (Calcium-D Tab 500 mg, 200 IU; Tehran
Darou, Iran) per day, orally. Patients in Group 2 received
1,000 mg of calcium and 400 IU of vitamin D as above,
plus metformin 1,500 mg/day (Metformin Tab 500 mg;
Minoo Darou, Iran), orally. Patients in Group 3 received
metformin 1,500 mg/day, orally. Treatment started on
the first day of menses and was continued for 3 months.
Patients were followed up 3 months after completion
of the treatment.
Regularity of menses according to interval (21–35
days), follicular growth, and pregnancy rate were com-
pared among the three groups. Pregnancy was con-
firmed by rising serum levels of β-human chorionic
gonadotropin and then by identification of a gestational
sac 2 weeks later. Follicular growth was categorized into
three groups according to the size of the follicle
(5–9 mm, 10–14 mm [borderline] and ≥ 14 mm [large])
using transvaginal sonography at mid-cycle. Data analy-
sis was performed using SPSS version 11 (SPSS Inc.,
Chicago, IL, USA). Differences were considered to be sta-
tistically significant at p < 0.05, and confidence intervals
of 95% were used. The data were analyzed using Chi-
squared, analysis of variance (ANOVA), Kruskal-Wallis
and multivariate regression tests (generalized estima-
tion equation tests [GEE]).
Results
Sixty infertile women with PCOS were enrolled in this
study. Their mean age was 25.91 ± 4.23 years, and their
mean body mass index (BMI), calculated as the weight
in kilograms divided by height in meters squared (kg/m2),
was 26.16 ± 3.95. ANOVA showed no significant differ-
ences in these variables among the three groups (Table
1). Dietary habits were compared among the groups
using a questionnaire and 24-hour dietary recall. Infor-
mation was collected on consumption of dairy products,
protein and fat. Kruskal-Wallis tests showed that the
consumption of dairy products was below the recom-
mended daily allowance in more than 60% of subjects.
Mean serum calcium level (9.62 ± 0.84 mg/dL) and
mean urinary calcium concentration (189.81 ± 83.22
mg/dL) were within the normal range (8.6–10.2 mg/dL
and 50–300 mg/dL for serum and urinary samples,
respectively).
About 80–100% of the subjects in all three groups had
a history of oligomenorrhea/amenorrhea during the last
6 months prior to the study (Table 2). Menstrual regular-
ity was reported after the third month of intervention
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in 30%, 50% and 35% of women in Groups 1, 2 and 3,
respectively (Table 3). Chi-squared tests showed no sig-
nificant difference in menstrual regularity among the
three groups after treatment (p=0.400), although it was
more obvious in the calcium-metformin group.
The frequency distribution of menstrual periods
showed that normal menstrual cycles were more frequent
in women with normal BMIs (BMI, 25–27), compared
with women with abnormal BMIs (44.5% in the normal
BMI group and 32% in the abnormal BMI groups). Chi-
squared and regression analyses showed no significant
differences in regularity of menstrual cycles among 
the three BMI groups (BMI < 25, BMI 25–27, and 
BMI > 27). There was no significant correlation between
follicular response to therapy and BMI.
Multivariate regression analysis and GEE tests were
used to compare treatment effects among the three
groups (Table 4). As shown in Table 5, follicular
response was relatively higher in Group 1 compared with
Group 3, but the difference was not significant
(p = 0.2896). The growth of follicles after treatment
was significantly higher in Group 2 than in Group 1
(p = 0.0372). The likelihood of treatment response was
about twice as high in Group 2 as in Group 1 (odds
ratio, 2.01). The relative frequency of response to treat-
ment in Group 2 was higher than in the other two
groups during the fifth and sixth months of the follow-
up period (Table 5).
Chemical pregnancy did not occur during the follow-
up period in any of the three intervention groups.
Table 1. Patients’ characteristics*
Variable
Group 1 Group 2 Group 3
Total p†
(Ca-D; n = 20) (Ca-D + met; n = 20) (met; n = 20)
Age (yr) 24.95 ± 3.56 25.805 ± 4.61 26.95 ± 4.44 25.91 ± 4.23 0.33
BMI 25.75 ± 3.94 27.81 ± 3.78 25.162 ± 3.860 26.16 ± 3.95 0.108
Duration of infertility (yr) 5.08 ± 3.85 5.52 ± 2.74 4.67 ± 3.31 5.09 ± 3.29 0.727
Plasma calcium (mg/dL) 9.84 ± 0.73 9.43 ± 0.71 9.61 ± 1.03 9.62 ± 0.84 0.306
Urinary calcium (mg/dL) 186.26 ± 86.6 181.7 ± 70.64 201/89 ± 94.44 189.81 ± 83.22 0.738
FSH (mIU/mL) 5.20 ± 1.98 4.95 ± 1.66 5.67 ± 1.70 5.28 ± 1.78 0.438
LH (mIU/mL) 9.90 ± 3.58 10.24 ± 6.38 8.81 ± 4.51 9.65 ± 4.91 0.640
Prolactin (mg/mL) 200.06 ± 198.75 216.66 ± 221.25 334.153 ± 259.02 248.87 ± 231.0 0.145
Serum magnesium (mg/L) 2.17 ± 0.23 2.07 ± 0.24 2.12 ± 0.29 2.12 ± 0.26 0.528
*Data are presented as mean ± standard deviation; †analysis of variance test, all p values are not significant. Ca-D = calcium-vitamin D; met = metformin; BMI =
body mass index; FSH = follicle-stimulating hormone; LH = luteinizing hormone.
Table 2. Patients’ characteristics*
Variable
Group 1 Group 2 Group 3
p† χ2
(Ca-D; n = 20) (Ca-D + met; n = 20) (met; n = 20)
Type of infertility 0.732 0.62
Primary 17 (85) 15 (75) 16 (80)
Secondary 3 (15) 5 (25) 4 (20)
Oligomenorrhea 0.126 4.1
Yes 20 (100) 20 (100) 18 (90)
No 0 (0) 0 (0) 2 (10)
Amenorrhea 0.308 2.35
Yes 2 (10) 5 (25) 2 (10)
No 18 (90) 15 (75) 18 (90)
History of oligomenorrhea 0.108 4.44
(in last 6 months)
Yes 18 (90) 20 (100) 16 (80)
No 2 (10) 0 (0) 4 (20)
History of amenorrhea 0.153 3.75
(in last 6 months)
Yes 2 (10) 5 (25) 2 (10)
No 18 (90) 15 (75) 18 (90)
*Data are presented as n (%); †all p values are not significant. Ca-D = calcium-vitamin D; met = metformin.
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Discussion
PCOS is recognized as one of the most common female
endocrine disorders, and is characterized by hyperan-
drogenic chronic anovulation with infertility, irregular
menses, and hirsutism [15].
Previous studies demonstrated a role for calcium in
oocyte maturation in invertebrates and amphibians,
and this role has been confirmed in mammals [16–18].
Another study showed that the calcium channel
blocker, verapamil tetracaine, caused oocyte arrest in
meiosis [19].
Recent research suggests that low levels of vitamin D
may be a primary factor in the initiation and develop-
ment of PCOS, and that dietary repletion of this
important vitamin could help to restore normal men-
strual cycles in women with this condition [20,21].
The combination of dietary calcium insufficiency and
Table 3. Regularity of menses after treatment in the treatment groups*†
Menstrual cycle Group 1 Group 2 Group 3
after treatment (Ca-D; n = 20) (Ca-D + met; n = 20) (met; n = 20)
Regular 6 (30) 10 (50) 7 (35)
Irregular 14 (70) 10 (50) 13 (65)
*Data are presented as n (%); †p = 0.400, χ2 = 0.83. Ca-D = calcium-vitamin D; met = metformin.
Table 5. Follicular growth after treatment in the three treatment groups*
Follicular response
Group 1 Group 2 Group 3
(Ca-D; n = 20) (Ca-D + met; n = 20) (met; n = 20)
Follicular response to treatment in 
third month
No 19 (95%) 15 (75%) 19 (95%)
Borderline (10–14 mm) 1 (5%) 2 (10%) 0 (0)
Yes (≥ 14 mm) 0 (0) 3 (15%) 1 (5%)
Follicular response to treatment in 
fourth month
No 19 (95%) 13 (65%) 15 (75%)
Borderline (10–14 mm) 1 (5%) 5 (25%) 2 (10%)
Yes (≥ 14 mm) 0 (0) 2 (10%) 3 (15%)
Follicular response to treatment in 
fifth month
No 16 (80%) 12 (60%) 14 (73.7%)
Borderline (10–14 mm) 0 (0) 2 (10%) 4 (21.1%)
Yes (≥ 14 mm) 4 (20%) 6 (30%) 1 (5.3%)
Follicular response to treatment in 
sixth month
No 15 (78.9%) 12 (63.2%) 15 (78.9%)
Borderline (10–14 mm) 0 (0) 2 (10.5%) 1 (5.3%)
Yes (≥ 14 mm) 4 (21.1%) 5 (26.3%) 3 (15.8%)
*Data are presented as n (%). Ca-D = calcium-vitamin D; met = metformin.
Table 4. The regression analysis (generalized estimation equation tests)
Parameter Estimate SE Z p
Intercept 1 −2.4987 0.4119 −6.07 < 0.0001
Intercept 2 −1.9376 0.4075 −4.75 < 0.0001
Group 3 (met) 0.4327 0.6086 1.06 0.2896
Group 2 (Ca-D + met) 0.6995 0.3357 2.08 0.0372
Group 1 (Ca-D) Reference group
SE = standard error; Ca-D = calcium-vitamin D; met = metformin.
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vitamin D deficiency may be largely responsible for the
menstrual abnormalities associated with PCOS [13].
Our study included a 3-month treatment period and
a 3-month follow-up period in three groups of 20
women with PCOS, most of whom had oligomenorrhea.
We assessed the effects of calcium plus vitamin D on
menstrual irregularities and infertility. Improvements
in menstrual irregularities were more noticeable in the
calcium-metformin group, though the differences among
the groups were not significant, possibly because of the
small sample sizes. It is possible that a large, randomized
clinical study with an increased sample size might be
able to demonstrate a clearer relationship between
calcium-metformin treatment and menstrual regularity.
A study performed by Thys-Jacobs et al [13] on the ef-
fects of calcium-vitamin D (1,500 mg) in 13 women
with PCOS showed that menstrual irregularities were
corrected in seven subjects after 2 months of treatment.
We found a statistically significant difference be-
tween the calcium-metformin and calcium groups in
terms of follicular growth, using GEE regression analy-
sis. This means that there was a better response to treat-
ment in the calcium-metformin group than in the other
two groups, especially in the second and third months
of follow-up. Follicular development following calcium
therapy has been confirmed in animal studies [10]. In
the study performed by Velazquez et al [22], fertility
was restored in PCOS patients after 6 months’ met-
formin therapy that reduced insulin and androgen 
levels, thus regulating menstrual cycles.
In the current study, the consumption of dairy prod-
ucts was below the recommended daily allowance in
more than 60% of patients in all the groups (less than
1,500 mg/day of calcium-rich foods, such as milk, yo-
ghurt, lassi, cheese, butter or dried whey). However, the
mean serum calcium concentrations in all the subjects
were still within the normal range. Another study found
low levels of intracellular calcium and abnormal oocyte
function, even though extracellular calcium levels were
within the normal range [12].
The inadequate dietary calcium intake by these pa-
tients and the role of calcium-vitamin D in bone health
and fertility suggest possible routes for treatment of
these patients. It appears that the combined use of
these two drugs (calcium-vitamin D plus metformin) 
is more effective for correcting menstrual disorders
and maturation of follicles than either drug alone.
More widespread epidemiologic, laboratory and clini-
cal studies on the role of calcium-vitamin D in follicu-
lar maturation in humans are needed to clarify their
roles in oocyte maturation. Better understanding of
these mechanisms would allow us to take more cost-
effective steps in the treatment of PCOS patients.
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